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Abstract: Collagen-based scaffolds hold great potential for tissue engineering, since they closely mimic
the extracellular matrix. We investigated tissue integration of an engineered porous collagen-elastin
scaffold developed for soft tissue augmentation. After implantation in maxillary submucosal
pouches in 6 canines, cell invasion (vimentin), extracellular matrix deposition (collagen type I)
and scaffold degradation (cathepsin k, tartrate-resistant acid phosphatase (TRAP), CD86) were
(immuno)-histochemically evaluated. Invasion of vimentin+ cells (scattered and blood vessels) and
collagen type I deposition within the pores started at 7 days. At 15 and 30 days, vimentin+ cells
were still numerous and collagen type I increasingly filled the pores. Scaffold degradation was
characterized by collagen loss mainly occurring around 15 days, a time point when medium-sized
multinucleated cells peaked at the scaffold margin with simultaneous labeling for cathepsin k, TRAP,
and CD86. Elastin was more resistant to degradation and persisted up to 90 days in form of packages
well-integrated in the newly formed soft connective tissue. In conclusion, this collagen-based scaffold
maintained long-enough volume stability to allow an influx of blood vessels and vimentin+ fibroblasts
producing collagen type I, that filled the scaffold pores before major biomaterial degradation and
collapse occurred. Cathepsin k, TRAP and CD86 appear to be involved in scaffold degradation.
Keywords: collagen; elastin; scaffold; biomaterial; tissue engineering; tissue response; wound healing;
degradation; immunohistochemistry
1. Introduction
Collagen is the most abundant extracellular matrix protein in the body. Besides having
important structural functions, collagen supports cell attachment, cell differentiation, repair, and tissue
regeneration [1,2]. Biomaterials in the form of collagen-based scaffolds hold great promise for both
bone and soft tissue engineering to replace damaged or lost tissues, since these biomaterials provide
an environment close to the native extracellular matrix [3–5]. Collagen-based scaffolds should at least
provide: (1) high biocompatibility, (2) a highly porous structure with interconnected pores to allow
influx of progenitor cells and blood vessels, (3) mechanical properties similar to the native tissue and (4)
degradation properties and kinetics that match the characteristic speed of the tissue to be regenerated.
The mechanical and degradation properties of collagen-based scaffolds can be tuned by altering the
ratio between collagen and elastin on one hand, and by the type and degree of chemical cross-linking
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on the other hand [6]. Collagen provides mechanical strength and stiffness, whereas elastin is
responsible for elasticity. Cross-linking, in general, enhances both structural stability and resistance
against degradation.
The autologous connective tissue graft from the palate is still the gold standard for soft tissue
augmentations in the oral cavity, but because of additional time and morbidity, the search is still
going on for the ideal biomaterial to replace the autologous graft. Lately, a collagen-based scaffold
with interconnected pores from porcine origin was developed for soft tissue augmentation around
teeth and dental implants [7]. Mechanical testing showed that the scaffold remained elastic for at
least 14 days [8]. Although preclinical studies showed promising results in terms of the gain in tissue
thickness, the biology behind it remains largely unknown. We previously demonstrated that this
biomaterial elicits a short inflammatory phase followed by rapid cell proliferation and the fast influx of
blood vessels and mesenchymal cells [9]. What occurs inside the scaffold pores, and how the scaffold
degrades and becomes integrated in the host tissue, is still not known.
The aim of the present study was therefore to characterize the invading cells, to evaluate
extracellular matrix deposition within the scaffold pores, and to assess scaffold degradation over a
period of 90 days. To this end, a canine implantation model was used [9] and immunohistochemistry
with antibodies against vimentin (for mesenchymal cells), collagen type I (for extracellular matrix
formation), and cathepsin K, tartrate-resistant acid phosphatase (TRAP) and CD86 (for scaffold
degradation) were applied. Furthermore, collagen type I deposition was histomorphometrically
quantified to show the dynamics of extracellular matrix formation, both into the scaffold and over time.
2. Materials and Methods
The present study had been approved by NAMSA Ethical Committee (ID number: 0041573)
and had been performed following the policies and principles of the Organization for Economic
Cooperation and Development Good Laboratory Practice regulations and the European Union
Guidelines (86/609/EEC).
Production of the collagen-based scaffold (Fibro-Gide® prototype, Geistlich, Wolhusen,
Switzerland) involved isolating, processing and milling two collagenous tissues, followed by mixing
the materials at a 3.5–4.5:0.5–1.5 ratio in an aqueous slurry. After freeze-drying, the resulting composite
was treated with a crosslinking agent, washed with water, freeze-dried again, and terminally sterilized
by gamma irradiation. The detailed production process is proprietary. The final product was composed
of 60%–96% (w/w) porcine collagen type I and III and 4%–40% elastin. Furthermore, the average pore
diameter was 92 µm and the volume porosity was 93% with interconnected pores, as determined
by mercury intrusion porosimetry [8]. Chemical cross-linking was used to increase the stiffness
of the scaffold. The critical mechanical properties were described by retention hysteresis under
repetitive compressive load of 12.1 kPa, whereby the first order retention was less than 45% after
49 cycles. This equated to a thickness retention after successive loading cycles of more than 85%.
The measurements were carried out in saline solution at 37 ◦C.
2.1. Surgical Phase
A concise description of the protocol concerning the animal selection and surgical phase is
described in a recent publication [10]. Briefly, in six mature dogs with a weight between 11.6 and
14.5 kg, the maxillary premolars were atraumatically extracted to create one edentulous space on
each side of the maxilla. After 90 days, a full thickness flap was elevated and a collagen-based
scaffold (Fibro-Gide® prototype, Geistlich, Wolhusen, Switzerland), measuring 6 mm × 6 mm × 10 mm,
was placed between the bone and the repositioned buccal flap. The wounds were closed by primary
intention. Sacrifice of animals was performed after 4 h and at days 4, 7, 15, 30 and 90.
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2.2. Histologic Processing and Descriptive Analysis
After resection, the maxillary samples were immediately immersed in 10% buffered formalin.
Upon arrival in the histology laboratory, the tissue samples were trimmed and immersed in
4% formalin for 10 days. To perform demineralization, tissue samples were immersed in 10%
ethylenediaminetetraacetic acid (EDTA) for 25 days. Samples were divided in thirds and embedded
in paraffin, methylmethacrylate (MMA) or in acrylic resin (LR White, Sigma-Aldrich, Saint Louis,
MO, USA). Paraffin sections were cut at 5 µm, while MMA-embedded tissues were cut with a
diamond-coated disc and ground to a thickness of 100 µm. LR White sections were cut at 1 µm
with a diamond knife on a Reichert Ultracut E microtome (Leica Microsystems, Wetzlar, Germany).
MMA-embedded sections were stained with basic fuchsin and toluidine blue and LR White-embedded
sections were double stained with toluidine blue and basic fuchsin. Tissue sections embedded in
paraffin were stained with hematoxylin/eosin and Giemsa. Immunohistochemical staining with
antibodies that target proteins expressed in mesenchymal cells (Vimentin), in M2 phenotypes of the
macrophage cell lineage (CD86), in the newly formed extracellular matrix (collagen type I), and in
proteases involved in extracellular matrix degradation (Cathepsin K) was applied. In addition,
histochemical staining for tartrate-resistant acid phosphatase (TRAP), an enzyme expressed during
mineralized tissue degradation and in soft tissue pathologies, was performed. Micrographs were taken
using a digital camera (AxioCam MRc, Carl Zeiss, Oberkochen, Germany), connected to a microscope
(Axio Imager M2, Carl Zeiss, Oberkochen, Germany). Observations were made in two regions of the
scaffold; at the periphery next to the bone and at the center of the scaffold.
2.3. Preparation for Vimentin Immunohistochemistry
Sections embedded in paraffin underwent immunohistochemical staining with an anti-vimentin
antibody (clone V9, Vimentin, Sigma, Saint Louis, MO, USA). Blocking with defatted milk
was performed for 30 min and Dako EnVisionTM + Dual Link System-HRP (DAB+) was used.
Incubation with the antibody was during 2 h at room temperature. The antibody was diluted 1:2000.
Samples were counterstained using Mayer’s hematoxylin solution (Merck, Darmstadt, Germany).
2.4. Preparation for Collagen Type I Immunohistochemistry
Sections embedded in paraffin underwent immunohistochemical staining with an anti-collagen
type 1 antibody (clone 6308, Collagen 1, Abcam, Cambridge, UK). Heat-induced epitope retrieval was
performed at 80–82 ◦C for 10 min with a citrate solution. Blocking with defatted milk was performed
for 30 min and Dako EnVisionTM + Dual Link System-HRP (DAB+) was used. Incubation with the
antibody was done for 2 h at room temperature. The antibody was diluted 1:100. Samples were
counterstained using Mayer’s hematoxylin solution (Merck, Darmstadt, Germany).
2.5. Quantitative Analysis of Collagen Type I
For the quantitative analysis of collagen type I, 3 animals were used (7, 15, and 30 days of healing),
because collagen deposition in the scaffold was not observed at 4 h and at 4 days, and 90 days was not
of interest because the active phase of collagen synthesis and deposition was over and replaced by
tissue remodeling. The area fractions of labeled collagen type I were determined in high-resolution
images in 5 rectangles per section and region (i.e., 5 rectangles in the periphery and 5 sections in the
center of the collagen-based scaffold). The rectangle size was 0.5 mm × 0.75 mm (area = 0.375 mm2).
The central rectangles were placed immediately adjacent to the peripheral rectangles. The rectangles
in the periphery were all evenly distributed on the bone side with similar distances between them,
the same was true for the central rectangles. The Zeiss Zen software (Zeiss, Oberkochen, Germany) was
used to capture the DAB-stained collagen type I and to convert the values into percentages: (labeled
area/total area) × 100.
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2.6. Preparation for Giemsa Histochemistry
Paraffin-embedded tissue sections were treated with Giemsa staining using Giemsa stock-solution
(T862.2, Carl Roth GmbH, Karlsruhe, Germany), as recommended by the manufacturer.
2.7. Preparation for Tartrate-Resistant Alkaline Phosphatase (TRAP) Histochemistry
Sections embedded in paraffin underwent tartrate-resistant acid phosphatase (TRAP) histochemical
staining. Sections were treated with azo staining using naphthol AS-TR phosphate (Fluka, Sigma-Aldrich,
Saint Louis, MO, USA), coupled with fast red violet TR salt (Chroma, Stuttgart, Germany).
2.8. Preparation for Cathepsin K Immunohistochemistry
Sections embedded in paraffin underwent immunohistochemical staining with an anti-cathepsin
K antibody (clone 19027, cathepsin K, Abcam, Cambridge, UK). Blocking with defatted milk
was performed for 30 min and Dako EnVisionTM + Dual Link System-HRP (DAB+) was used.
Incubation with the antibody was done for 1.5 h at room temperature. The antibody was diluted 1:500.
Samples were counterstained using Mayer’s hematoxylin solution (Merck, Darmstadt, Germany).
2.9. Preparation for CD86 (B7-2) Immunohistochemistry
Sections embedded in paraffin underwent immunohistochemical staining with an
anti-CD86 antibody (clone EP1158Y, CD86, Abcam, Cambridge, UK). Heat-induced epitope retrieval
was performed at 85 ◦C for 10 min with a citrate solution. Blocking with defatted milk was performed
for 30 min and Dako EnVisionTM + Dual Link System-HRP (DAB+) was used. Incubation with the
antibody was done for 2 h at room temperature. The antibody was diluted 1:100. Samples were
counterstained using Mayer’s hematoxylin solution (Merck, Darmstadt, Germany).
3. Results
Healing of the animals did not present complications. Tissue samples were collected and processed
for histological analysis according to the Material and Methods section. Wound healing outside the
biomaterial was normal, as reported recently [9]. Histological inspection revealed that the porous
collagen-based scaffold (Figure 1A) was present close to the bone surface at all healing periods
(Figure 1B). The scaffold presented a large honeycomb-like interconnected porous structure (Figure 1A),
consisting of an amorphous, sheet-like matrix (i.e., the collagenous part of the scaffold), with embedded,
rod-like structures (i.e., the elastin part of the scaffold) (Figure 1C) and pores that were rapidly
filled with fluid and blood cells (Figure 1C). At 90 days, residual scaffold material was still visible.
It consisted of islands of the rod-like scaffold part, that were dispersed among, and well-integrated in,
the surrounding host soft connective tissue (Figure 1D). For reasons of consistency and standardization,
the following description of the results will be confined to the region facing the bone surface.
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Figure 1. Scanning electron microscopic image illustrating the three-dimensional-structure of the 
scaffold (A). Overview of a methylmethacrylate (MMA)-embedded tissue section showing the 
scaffold between the bone and the soft connective tissue 4 days after implantation (B). The resin 
section illustrates the pores of the scaffold filled with blood plasma and erythrocytes after 4 days (C). 
Resin section 90 days after implantation of the scaffold showing elastin fiber packages integrated in 
the host tissues (D). 
3.1. H&E Staining 
Up to day 7, the central part of the scaffold showed a clear delay in the invasion of blood vessels 
and mesenchymal-like cells and extracellular matrix formation when compared to the peripheral 
part. Immediately after implantation, the pores of the scaffold were mainly filled with erythrocytes 
and blood plasma/wound fluid (Figure 2A,G). At 4 days, a fibrin network with trapped leukocytes 
was present within most scaffold pores (Figure 2B,H) and small blood vessels were seen in the soft 
connective tissue next to the scaffold (Figure 2B). Very few blood vessels and mesenchymal-like cells 
were seen in the outermost portion of the scaffold. At 7 days, blood vessels gradually grew in the 
scaffold pores and increased in size and number at the periphery, and the number of invading 
mesenchymal-like cells increased as well (Figure 2C). Furthermore, the pores became filled with an 
extracellular matrix (Figure 2C). Compared to the periphery (Figure 2C), this development was less 
advanced in the central part of the scaffold (Figure 2I). After 15 days, more blood vessels were seen 
in the scaffold pores, the mesenchymal-like cells inside the pores had increased in quantities, and 
extracellular matrix fill was more advanced (Figure 2D,K). At 30 days, many blood vessels, 
mesenchymal-like cells now resembling thin fibroblasts, and an extracellular matrix, filled the 
scaffold pores both in the peripheral (Figure 2E) and central (Figure 2L) part of the scaffold. At 90 
days, packages of condensed residual scaffold elastin were fully integrated in the host soft connective 
tissue (Figure 2F,M). 
Figure 1. Scanning electron icroscopic i age illustrating the three-di ensional-structure of the
scaffol (A). Overview of a methylmethacrylate (MMA)-embedded tissue section showing the scaffold
between the bone and the soft connective tissue 4 days after implantation (B). The resin section illustrates
the pores of the scaffold filled with blood plasma and erythrocytes after 4 da s (C). Resin section 90 days
after implantation of the scaffold showi g elastin fiber packages integrated in the host tissues (D).
3.1. H&E Staining
Up to day 7, the central part of the scaffold showed a clear delay in the invasion of blood vessels
and mesenchymal-like cells and extracellular matrix formation when compared to the peripheral part.
Immediately after implantation, the pores of the scaffold were mainly filled with erythrocytes and blood
plasma/wound fluid (Figure 2A,G). At 4 days, a fibrin network ith trapped leukocytes was present
within most scaffold pores (Figure 2B,H) and small blood vessels were seen in the soft connective
tissue next to the scaffold (Figure 2B). Very few blood vessels and mesenchymal-like cells were seen in
the outermost portion of the scaffold. At 7 days, blood vessels gradually grew in the scaffold pores
and increased in size and number at the periphery, and the number of invading mesenchymal-like
cells increased as well (Figure 2C). Furthermore, the pores became filled with an extracellular matrix
(Figure 2C). Compared to the periphery (Figure 2C), this development was less advanced in the central
part of the scaffold (Figure 2I). After 15 days, more blood vessels were seen in the scaffold pores,
the mesenchymal-like cells inside the pores had increased in quantities, and extracellular matrix fill was
more advanced (Figure 2D,K). At 30 days, many blood vessels, mesenchymal-like cells now resembling
thin fibroblasts, and an extracellular matrix, filled the scaffold pores both in the peripheral (Figure 2E)
and central (Figure 2L) part of the scaffold. At 90 days, packages of condensed residual scaffold elastin
were fully integrated in the host soft connective tissue (Figure 2F,M).
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Figure 2. Tissue sections embedded in paraffin and stained with H&E showing the scaffold (black 
arrows) at different time points at the periphery and the center. Immediately after implantation and 
after 4 days, the pores of the scaffold are mainly filled with blood plasma/wound fluid and 
erythrocytes (A,B,G,H). At 4 days, blood vessels (blue arrows) can be seen adjacent to the scaffold, 
but not penetrating it (B). At 7 days, cells start to invade the scaffold from the periphery and initial 
filling of the pores with extracellular matrix begins (C), while these cells do not reach the central 
portion yet (I). At 15 days, blood vessels are clearly seen in the scaffold pores both at the periphery 
(D) and in the center (K), while mesenchymal-like cells inside the pores have increased in amounts, 
and extracellular matrix fill is more advanced (D,K). At 30 days, blood vessels increase in number at 
the periphery (E) and in the center of the scaffold (L) and newly formed tissue within the pores 
presents a compact structure throughout the scaffold (E,L). At 90 days, dense packages of residual 
elastin (yellow circles) are present at the periphery and the center of the scaffold, along with large 
blood vessels external to the scaffold and smaller blood vessels in the newly formed soft connective 
tissue around the residual elastin (F,M). 
3.2. Immunohistochemistry with the Anti-Vimentin Antibody 
Vimentin labeling in the scaffold pores was observed, both in scattered cells and blood vessels. 
Vimentin+ scattered cells and blood vessels were located in the connective soft tissue next to the 
scaffold at 4 days (Figure 3A). No labeled cells were seen in the peripheral scaffold pores at 4 days 
(Figure 3A) and in the central part of the scaffold at 4 (Figure 3F) and 7 days (Figure 3G). However, 
many vimentin+ scattered cells and blood vessels were seen in the peripheral scaffold pores at 7 days 
(Figure 3B). At 15 days, many vimentin+ scattered cells and blood vessels occupied the scaffold pores 
(Figure 3C,H), and more vimentin+ cells were observed in the periphery (Figure 3C) than in the 
central part (Figure 3H). At 30 days, most of the vimentin+ cells were located in the center of the 
scaffold (Figure 3I), while some vimentin positive cells could still be found in the peripheral pores 
and in the external host tissue (Figure 3D). At 90 days, vimentin+ cells were mainly distributed in the 
host connective tissue surrounding the residual scaffold packages, with no differences between 
peripheral and central regions (Figure 3E,K). The negative controls did not show positive labeling for 
vimentin (data not shown). 
Figure 2. Tissue sections e bedded in paraffin and stained with H&E showing the scaffold (black
arro s) at different ti e points at the periphery and the center. I ediately after i plantation and
after 4 days, the pores of the scaffold are mainly filled with blood plasma/wound fluid and erythrocytes
(A,B,G,H). At 4 days, blood vessels (blue arrows) can be seen adjacent to the scaffold, but not penetrating
it (B). At 7 days, cells start to invade the scaffold from the periphery and initial filling of the pores with
extracellular matrix begins (C), while these cells do not reach the central portion yet (I). At 15 days,
blood vessels are clearly seen in the scaffold pores both at the periphery (D) and in the center (K), while
mese chymal-like c lls inside the por s have increased in amounts, and xtr c llular matrix fill is more
dvanced (D,K). At 30 days, blood vessels increase in number at the periphery (E) and in the cent r of
t scaffold (L) and ewly form d tissue within the pores presents a compact structure t roughout the
scaffold (E,L). At 90 days, dense packages of r sidual elastin (yellow circles) are present at the periphery
and the c nter of the caffold, alo g wi large blood vessels external to ff l and smaller blood
vessels in the newly formed soft c nnective tissue ar und the residual elastin (F,M).
3.2. Immunohistochemistry with the Anti-Vimentin Antibody
Vi entin labeling in the scaffold pores was observed, both in scattered cells and blood vessels.
Vimentin+ scattered cells and blood vessels were located in the connective soft tissue next to the scaffold
at 4 days (Figure 3A). No labeled cells were seen in the peripheral scaffold pores at 4 days (Figure 3A)
and in the central part of the scaffold at 4 (Figure 3F) and 7 days (Figure 3G). However, many vimentin+
scattered cells and blood vessels were seen in the peripheral scaffold pores at 7 days (Figure 3B).
At 15 days, many vimentin+ scattered cells and blood vessels occupied the scaffold pores (Figure 3C,H),
and more vimentin+ cells were observed in the periphery (Figure 3C) than in the central part (Figure 3H).
At 30 days, most of the vimentin+ cells were located in the center of the scaffold (Figure 3I), while
some vimentin positive cells could still be found in the peripheral pores and in the external host
tissue (Figure 3D). At 90 days, vimentin+ cells were mainly distributed in the host connective tissue
surrounding the residual scaffold packages, with no differences between peripheral and central regions
(Figure 3E,K). The negative controls did not show positive labeling for vimentin (data not shown).
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Figure 3. Immunohistochemical staining for vimentin to label mesenchymal cells. Brown (DAB+) 
staining indicates vimentin+ mesenchymal cells. At four days, vimentin+ cells are located in the soft 
connective tissue around the collagen-based scaffold, but have not yet invaded it (A,F). At day 7, 
vimentin+ cells have invaded the periphery of the scaffold as scattered cells and blood vessels (blue 
arrows), but have not yet reached the center (B,G). At 15 days, numerous scattered cells and blood 
vessels positive for vimentin occupy the scaffold pores (C,H). At 30 days, most of the vimentin+ cells 
are located in the center of the scaffold (I), while some vimentin+ cells can still be found in the 
peripheral pores and in the external host tissue (D). Labeled cells with an elongated shape can be seen 
90 days after implantation in the in the soft connective tissue surrounding the residual scaffold, both 
at the periphery (E) and in the center (K). 
3.3. Immunohistochemistry with the Anti-Collagen Type I Antibody 
Inspection of the not injured soft connective tissue part of the oral mucosa and of bone revealed 
positive immunostaining for collagen type I. Immunostaining for collagen type I inside the 
biomaterial scaffold was first observed after 7 days. Collagen type I labeling progressively increased 
from the periphery to the central part of the scaffold and the area occupied with labeled collagen type 
I increased from 7 to 30 days (Figure 4). The labeling intensity was always stronger for the newly 
formed collagen inside the scaffold than for collagen in the surrounding soft connective tissue and in 
bone. There was no collagen type I immunostaining observed at all at 4 days in the periphery (Figure 
4A) and at 4 (Figure 4E) and 7 days (Figure 4F) in the central part of the scaffold. The first collagen 
type I immunostaining in the scaffold pores was seen at day 7 in the peripheral part (Figure 4B). At 
15 days, dense and compact structures positive for collagen type I were filling the pores of the scaffold 
at the periphery (Figure 4C). The first collagen type I immunostaining in the center of the scaffold 
was seen at 15 days (Figure 4G), but it was less dense than that in the periphery (Figure 4C). At 30 
days, the extracellular matrix positive for collagen type I was more dense and almost completely 
filled the scaffold pores irrespective of their location (Figure 4D,H). At 90 days, the extracellular 
matrix surrounding the residual scaffold occupied a large tissue portion and was positive for collagen 
type I (not shown). At all observation periods where positive labeling for collagen type I was 
observed, elongated and slender cells (fibroblasts) were seen intermingling with the newly formed 
collagen matrix. Negative controls did not show positive labeling for collagen type I (data not shown). 
Figure 3. I unohistoche ical staining for vi entin to label esenchy al cells. Brown (DAB+)
staining indicates vi entin+ esenchy al cells. At four days, vi entin+ cells are located in the soft
connective tissue around the collagen-based scaffold, but have not yet invaded it ( ,F). t day 7,
vi entin cells have invaded the periphery of the scaffold as scattered cells and blood vessels (blue
arro s), b t have not yet reache the center ( , ). t 15 ays, n ero s scattere cells an bloo
vessels ositive for vimentin occupy the scaffold pores (C,H). At 30 days, most of the vimentin+ cells are
located in the center of the scaffold (I), while some vimentin+ cells can still be found in the peripheral
ores and in the exter al host tissue (D). Lab led cells with an elong ted shape can be see 90 days
after implantation in the in the soft connective tissue surrounding the residual scaffold, both at the
periphery (E) and in the center (K).
3.3. Immunohistochemistry with the Anti-Collagen Type I Antibody
Inspection of the not injured soft connective tissue part of the oral mucosa and of bone revealed
positive immunostaining for collagen type I. Immunostaining for collagen type I inside the biomaterial
scaffold was first observed after 7 days. Collagen type I labeling progressively increased from the
periphery to the central part of the scaffold and the area occupied with labeled collagen type I increased
from 7 to 30 days (Figure 4). The labeling intensity was always stronger for the newly formed collagen
inside the scaffold than for collagen in the surrounding soft connective tissue and in bone. There was
no collagen type I immunostaining observed at all at 4 days in the periphery (Figure 4A) and at
4 (Figure 4E) and 7 days (Figure 4F) in the central part of the scaffold. The first collagen type I
immunostaining in the scaffold pores was seen at day 7 in the peripheral part (Figure 4B). At 15 days,
dense and compact structures positive for collagen type I were filling the pores of the scaffold at
the periphery (Figure 4C). The first collagen type I immunostaining in the center of the scaffold was
seen at 15 days (Figure 4G), but it was less dense than that in the periphery (Figure 4C). At 30 days,
the extracellular matrix positive for collagen type I was more dense and almost completely filled
the scaffold pores irrespective of their location (Figure 4D,H). At 90 days, the extracellular matrix
surrounding the residual scaffold occupied a large tissue portion and was positive for collagen type
I (not shown). At all observation periods where positive labeling for collagen type I was observed,
elongated and slender cells (fibroblasts) were seen intermingling with the newly formed collagen
matrix. Negative controls did not show positive labeling for collagen type I (data not shown).
Materials 2020, 13, 2420 8 of 14
Materials 2020, 13, x FOR PEER REVIEW 8 of 14 
 
 
Figure 4. Immunohistochemical staining for collagen type I to label newly formed collagen within the 
scaffold pores. Collagen type I is stained in brown (DAB+). No collagen type I immunostaining is 
observed at 4 days (A,E), or at 7 days in the center of the scaffold (F). Collagen type I starts to fill the 
scaffold pores at 7 days starting from the periphery (B). At 15 days, compact structures positive for 
collagen type I fill the pores at the periphery of the scaffold (C) and start filling the central pores (G). 
At 30 days, newly formed collagen type I fills the scaffold pores, irrespective of their location (D,H). 
3.4. Quantitative Histological Analysis for Collagen Type I 
Quantification of collagen type I immunostaining showed an increase in the area occupied by 
immunostaining from 7 to 30 days, both in the periphery and in the center of the scaffold (Figure 5). 
For days 7 and 15, the areas of collagen labeling were clearly larger in the periphery than in the center. 
At later time points, this difference was no more visible. In the center, the immunostained area 
significantly increased from day 7 to day 15 and from day 15 to day 30. 
i r . I unohistochemical staining for collagen type I to label newly formed collagen within
the scaffold pores. Collagen type I is stained in brown (DAB+). No collagen type I i st i i is
t ( , ), t i t t f t ff l ( ). ll t I t t t fill t
ff l t i t i . , i i
fi ff fi l .
, l f r ll t e I fills the scaffold pores, ir espective of their location (D,H).
3.4. Quantitative Histological Analysis for Collagen Type I
Quantification of collagen type I immunostaining showed an increase in the area occupied by
immunostaining from 7 to 30 days, both in the periphery and in the center of the scaffold (Figure 5).
For days 7 and 15, the areas of collagen labeling were clearly larger in the periphery than in the
center. At later time points, this difference was no more visible. In the center, the immunostained area
significantly increased from day 7 to day 15 and from day 15 to day 30.
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Figure 5. Quantitative analysis for collagen type I. An overall increase of collagen is observed over 
time. At 15 days, significantly more collagen is present in the periphery compared to the center of the 
scaffold. In the central part of the scaffold, significantly more collagen is present between 7 and 15 
days as well as between 15 and 30 days. * p < 0.05. 
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constituents underwent over time (Figure 6). The collagenous part was stained in dark purple, while 
the elastin part was stained in dark pink (Figure 6). At early time points, collagen and elastin of the 
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Figure 5. uantitative analysis for collagen type I. n overall increase of collagen is observed over
ti e. At 15 days, significantly ore collagen is present in the periphery co pared to the center of the
scaffold. In the central part of the scaffold, significantly more collagen is present between 7 and 15 days
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3.5. Degradation of the Scaffold
Resin sections stained with toluidine blue and basic fuchsin differentially stained the collagenous
and elastin parts of the scaffold and allowed therefore to study the alterations these two constituents
underwent over time (Figure 6). The collagenous part was stained in dark purple, while the elastin
part was stained in dark pink (Figure 6). At early time points, collagen and elastin of the scaffold
clearly stood out (Figure 6A–C). Later, the collagen part disappeared, leaving mainly elastin embedded
in newly formed collagen that stained bluish (Figure 6D,E). The light blue or purple color around the
elastin is newly formed collagen. At 90 days, only packages of elastin fibers were left and integrated
into the newly formed soft connective tissue (Figure 6F).Materials 2020, 13, x FOR PEER REVIEW 10 of 14 
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To evaluate the cell-mediated degradation of the scaffold, we studied the appearance of
multinucleated cells using Giemsa and TRAP histochemistry together with cathepsin K and
CD86 immunostaining (Figure 7). Giemsa staining gave a differential staining of multinucleated cells,
so that they stood out against the surrounding tissue elements (Figure 7A). Most multinucleated cells
were observed 15 days after scaffold implantation in the peripheral part of the scaffold (Figure 7A).
No multinucleated cells were detected at 4 h, and at 4 and 90 days; a few only at 7 and 30 days.
These multinucleated cells were medium-sized and in close contact to the scaffold surface. In the same
region as the image shown in Figure 7A, adjacent consecutive sections revealed cells of similar size that
were positive for cathepsin K (Figure 7B), TRAP (Figure 7C), and CD86 (Figure 7D). Before and after
15 days and in the center of the scaffold, no multinucleated cells positive for cathepsin K or CD86 were
found. Very few TRAP-positive cells remained in the scaffold up to day 30, mainly at the periphery
(data not shown). Negative controls did not show positive labeling for TRAP, cathepsin K or CD86
(data not shown).
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4. Discussion
The idea behind using biomaterials for tissue regeneration is to avoid the drawbacks of autogenous
tissue harvesting and transplantation [11]. Another advantage of biomaterials is their availability in
large amounts. Collagen is the most commonly used biomaterial to augment or regenerate soft tissues,
since collagen scaffolds mimic very well the natural extracellular matrix environment. Recently, we have
shown that the collagen-based scaffold tested in the present study preserved its porous structure after
implantation and presented a short inflammatory phase followed by rapid influx of blood vessels and
mesenchymal-like cells undergoing rapid cell proliferation [9]. The aim of the present study was to
characterize the invading cells, to evaluate extracellular matrix deposition within the scaffold pores,
and to assess scaffold degradation over a period of 90 days.
Our results demonstrate that vimentin-positive cells progressively invaded the pores of the
collagen-based scaffold, starting at day 7 in the periphery and reaching the center at day 15. The highest
numbers of vimentin-positive cells in the pores were seen at day 15 in the periphery and the center
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of the scaffold. The vimentin-positive cells were either scattered or associated with blood vessels.
The scattered cells became increasingly slender and elongated and were aligned parallel to the fibrous
extracellular matrix filling the scaffold pores. Interestingly, vimentin labeling was also associated
with the invading blood vessels. Vimentin, an intermediate cytoskeletal filament, is mainly expressed
in cells of mesenchymal origin [12] and is often used as a fibroblast marker. Vimentin is also
an important cytoskeletal filament in endothelial cells and plays a role in cell polarity, migration
and vascularization [12,13], as well as wound healing by controlling fibroblast proliferation [14].
Collectively, our data support that blood vessels, together with fibroblasts, invaded the scaffold pores.
Our immunohistochemical and histomorphometric data show that the pores of the collagen-based
scaffold became increasingly filled with collagen type I, starting at day 7 from the periphery and
progressing towards the center. At day 30, most of the pores were considerably filled with newly
formed collagen. The collagen type I labeling, together with the vimentin labeling, strengthens the
hypothesis that the invading cells are fibroblasts. Newly formed collagen type I can be specifically
stained using antibodies [15] or using histochemical stains such as Masson’s trichrome to study the
newly synthesized collagen fibrils, as shown in a recent publication where an elastin scaffold was
used for tissue engineering purposes of cardiovascular disorders [16]. Very recently, it was shown
that the physical characteristics of biomaterial scaffolds modulate macrophage response [17] and
polarization [18]. Macrophages are involved in tissue repair by regulating vascularization [19,20],
fibroblast proliferation and activity [21], and the rapid synthesis of collagen fibrils [22]. These data are
in line with our previous data, showing a burst of macrophages within the scaffold pores and their
rapid disappearance, as well as fast cell proliferation [9], and with the results from the present study
demonstrating fast ingrowth of vimentin-positive fibroblasts after the influx of macrophages, followed
by rapid collagen synthesis.
Recently, it was suggested that the scaffold tested undergoes degradation and that the collagenous
part degrades faster than the elastin fibers eventually leaving elastin fibers for a longer period of time
within the tissue [9]. Here, we show now that markers associated with matrix degradation were almost
exclusively expressed at 15 days after scaffold implantation. The expression of cathepsin K, TRAP,
and CD86 was mainly found in medium-sized multinucleated cells at the interface between scaffold
and neighboring connective soft tissue. Cathepsin K, a member of the cysteine proteases, has a high
matrix-degrading activity, especially for collagen type I [23,24]. Cathepsin K was initially thought to
be exclusively expressed in osteoclasts and therefore used as one of the cell markers for osteoclasts.
Cathepsin K expression, however, was also observed in epithelioid cells and multinucleated giant
cells in soft tissues, suggesting that these cells also possess proteolytic capability in non-mineralizing
tissues [17]. Multinucleated giant cells strongly express CD86 [25,26]. Thus, our results of CD86-positive
multinucleated cells suggest an involvement of these cells in the degradation of the collagen-based
scaffold. Co-localization of cathepsin K and CD86 has been described in macrophages related to
degradation and rupture of carotid plaques [27], but not in soft tissue biomaterials so far. Other studies
have already pointed to macrophages playing a role in biomaterial degradation [28,29]. Tartrate-resistant
acid phosphatase (TRAP), a proteolytic enzyme involved in bone matrix degradation, was originally
used as an osteoclast-specific marker. However, TRAP is now considered as a widespread molecule with
functions in hard and soft tissues and is expressed by osteoclasts, macrophages, dendritic cells, and other
cell types [30]. To the best of our knowledge, there are no other data in the literature showing expression
of TRAP in association with collagen degradation in soft tissues. Studies analyzing degradation of
collagen-based biomaterials have found CD86-positive cells within the biomaterial, but no TRAP
staining [31]. Since the collagenous part of the investigated scaffold underwent degradation, it is very
likely that TRAP was involved in this degradation process. Thus far, TRAP was mainly associated
with the degradation of the organic bone matrix. Taken together, our data suggest that medium-sized
multinucleated cells expressing at least cathepsin K, TRAP, and CD86 play a role in the degradation of
collagenous scaffolds. No data reporting on the co-localization of these three markers in macrophages
were found in the literature. It is very possible that cathepsin K and TRAP are involved in the
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degradation of the collagenous part of the scaffold, since up to day 7, the elastin fibers remained
embedded in the collagen matrix, whereas from day 15 on, elastin fibers appeared to be released
from the collagen-elastin scaffold (see Figure 6). At 90 days, only packages of elastin fibers were seen
embedded in newly formed host collagen fibers. A challenging task in biomaterial development for
soft tissue augmentation is to match the degradation time of the biomaterial with the extracellular
matrix formation dynamics, to avoid early biomaterial collapse. The present data indicate that this
balance is successfully achieved. A good ratio between collagen and elastin together with collagen
cross-linking may be responsible for this.
Like other studies, the present study also has limitations. One limitation is the small sample
size due to the study design, which aimed at studying the sequence of events over a period of
90 days, using 6 observation periods. The study may thus be considered as a pilot experiment
and the data as preliminary. Furthermore, only a negative control was used, i.e., sham-operated
sites. Future experiments may involve a larger number of tissue samples and other biomaterials,
for comparative reasons. Nevertheless, the study provides novel and unique data of clinical relevance
and for future studies in the biomaterial field.
5. Conclusions
Taken together, the results from the present and a recent study [9] demonstrate that the porous
scaffold elicits a short inflammatory phase, maintains long-enough volume stability to allow influx of
blood vessels and vimentin-positive fibroblasts producing collagen type I that fills the scaffold pores,
before major biomaterial degradation and collapse occurs. These histologic data form the rational
for the clinical application of this biomaterial for soft tissue augmentation around dental implants
and teeth. It needs to be determined whether this collagen-based scaffold can also be used as a tissue
engineering biomaterial for periodontal regeneration and the restoration of bone defects.
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